-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Researchers have found that adding a third drug to the commonly used dual-drug inhaler can reduce asthma attacks in children, adolescents, and adults with moderate to severe asthma, and improve disease control
A team from McMaster University and The Research Institute of St.
Dual-drug inhalers used to treat asthma usually contain an inhalable corticosteroid (ICS) to reduce inflammation, and a long-acting beta-adrenergic receptor agonist (LABA), which can act as a bronchodilator
The lead author of the study, Dr.
Dr.
"If we can achieve optimal control of the patient's asthma and reduce the rate of asthma exacerbation through Lama add-on therapy, patients can avoid other treatments at a higher risk of adverse events, such as oral glucocorticoids, or treatments that are significantly more expensive, such as biological agents," Lisa Kim said that a clinical scholar at McMaster Medical School is also a co-author of this study
Inhaled LAMAs are currently available in the form of a single inhaler or a three-in-one inhaler, and also include ICS and LABA
Among Canadians over the age of 12, more than 8% are diagnosed with asthma, which makes asthma the most common chronic disease in children
The study was published in the Journal of the American Medical Association (JAMA), and the author published a report at the Asthma Treatment Progress Symposium
# # #
